Use of unopposed estrogen in women with uteri: Prevalence, clinical implications, and economic consequence

Menopause

Volumn 7, Issue 2, 2000, Pages 123-128

  White, Virginia E ^a   Bennett, Lacrisha ^a   Raffin, Stephen ^a   Emmett, Kathleen ^b   Coleman, Marcia J ^b,c  

^a Foundation Health Plan   (United States)

^b WYETH AYERST RESEARCH   (United States)

^c WYETH AYERST RESEARCH   (United States)

Author keywords

Cost; Hormone replacement therapy; Hysterectomy; Menopause

Indexed keywords

ESTROGEN; GESTAGEN;

ARTICLE; ECONOMIC ASPECT; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RISK BENEFIT ANALYSIS; UTERUS;

EID: 0034099337     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200007020-00009     Document Type: Article

References (27)

1. Christiansen C, Christensen MS, Transbol I. Bone mass in post-menopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459-61.
2. Jensen GF, Christiansen C, Transbol I. Treatment of postmenopausal osteoporosis: a controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium. Clin Endocrinol 1982;16:515-24.
3. National Institutes of Health. Consensus Conference: osteoporosis - NIH Consensus Development Panel statement. JAMA 1984;252:799-802.
4. Falkeborn M, Persson I, Adami H, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-8.
5. Lobo RA. Estrogen and cardiovascular disease. Ann N Y Acad Sci 1990;592:286-94.
6. Sullivan JM, Vander Swaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease. Arch Intern Med 1990;150(12):2557-62.
7. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1991;154:1333-9.
8. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among post-menopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991;164:489-94.
9. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurse's Health Study. N Engl J Med 1991;325:756-62.
10. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990;97:1080-6.
11. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988;159:312-7.
12. Henderson BE, Ross RK, Paganini-Hill A, et al. Estrogen use and cardiovascular disease. Am J Obstet Gynecol 1986;154:1181-6.
13. Woodruff JD, Pickar JH for the Menopause Study Group. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-73.
14. Clisham PR, Cedars NU, Greendale G, Fu YS, Gambone J, Judd HL. Long-term transdermal estradiol therapy: effects on endometrial histology and bleeding patterns. Obstet Gynecol 1992;79:196-201.
15. The Postmenopausal Estrogen/Progestins Interventions (PEPI) Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 1996;275(5):370-5.
16. Berman RS. Patient compliance of women taking estrogen replacement therapy. Drug Inf J 1997;31:71-83.
17. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-12.
18. Silverman SL, Greenwald M, Klein RA, Drinkwater BL. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol 1997;89(3):321-5.
19. U.S. Bureau of the Census. Current population reports, series P25-1130. Population projections of the United States by age, sex, race, and Hispanic origin: 1995 to 2050. Washington, DC: U.S. Bureau of the Census, 1996.
20. American College of Obstetrics and Gynecology (ACOG). Hormone replacement therapy survey MRD WH-00-296. Washington, DC: American College of Obstetrics and Gynecology, 1996.
21. Riedel M, Rafflenbeul W, Lichtlen P. Ovarian sex steroids and atherosclerosis. Clin Invest 1993;71:406-12.
22. Gambrell RD Jr. The menopause: benefits and risks of estrogen-progestogen replacement therapy. Fertil Steril 1982;37(4):457-74.
23. Disaia PJ, Creasman WT. Clinical gynecologic oncology, 5th ed. St. Louis: Mosby-Yearbook, 1997.
24. Berg JS, Dischler J, Wagner DJ, Aia JJ, Palmer-Shevlin N. medication compliance: a healthcare problem. Ann Pharmacother 1993;27(Suppl. 9):S1-S24.
25. Hillard RC, Siddle NC, Whitehead MI, et al. Continuous combined conjugated equine estrogen-progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol 1992;167:1-7.
26. Spencer CP, Cooper AJ, Whitehead MI. Management of abnormal bleeding in women receiving hormone replacement therapy. BMJ 1997;315:37-42.
27. Dàren M, Schneider HPG. Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women. Maturitas 1996;25:99-105.